|
|
Article: Immunogenicities of Plasmodium vivax protein fragments compared.
- Article from:
- Life Science Weekly
- Article date:
- December 7, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 DEC 7 - (NewsRx.com & NewsRx.net) -- Scientists compare immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kilodalton fragments expressed in Escherichia coli in a recent issue of Infection and Immunity.
"The 42- and 19-kDa C-terminal fragments of merozoite surface protein 1 (MSP-1[subscript]42 and MSP-1[subscript]19, respectively) are both promising blood-stage vaccine candidate antigens. At present, it is not clear which of the two antigens will be more suitable for inclusion in a cocktail malaria vaccine. In the present study, we expressed the two C-terminal fragments of Plasmodium vivax MSP-1 (PvMSP-1) in an ...